SCHEMBL23055173

SCHEMBL23055173

CCC(c1ccc(F)cc1)c1ncccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP2D6 P10635 1/20 0.36
CHRM1 P11229 1/20 0.36
HRH1 P35367 1/20 0.36
KCNH2 Q12809 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
CYP19A1 P11511 2/20 0.35
TSHR P16473 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
CNR1 P21554 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALOX12 P18054 1/20 0.35
POLB P06746 1/20 0.35
EPHX2 P34913 1/20 0.35
HTT P42858 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23055144 0.88 HRH1 (0.45) CYP17A1MEN1KMT2ACYP2D6CHRM1
SCHEMBL23589087 0.78 CYP2D6 (0.40) CYP17A1CYP2D6CHRM1HRH1KCNH2
SCHEMBL25483685 0.76 TRPM8 (0.33) MEN1KMT2ACYP2D6CHRM1HRH1
SCHEMBL21911307 0.75 SLC6A2 (0.54) MEN1KMT2ACYP2D6CHRM1HRH1
SCHEMBL21911308 0.75 TRPM8 (0.39) CYP17A1CYP2D6CHRM1HRH1KCNH2
SCHEMBL21910135 0.75 LMNA (0.45) CYP17A1MEN1KMT2ACYP2D6ALDH1A1
SCHEMBL21831471 0.75 LMNA (0.40) KMT2ATRPM8POLBSMN1; SMN2NFE2L2
SCHEMBL30910865 0.75 NFE2L2 (0.36) MEN1KMT2ATRPM8CYP19A1POLB
SCHEMBL21911318 0.75 NFE2L2 (0.36) MEN1KMT2ATRPM8CYP19A1POLB
SCHEMBL14407028 0.75 S1PR1 (0.36) KMT2ATRPM8ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG CYP17A1 4265/4885MEN1 2784/4885KMT2A 2162/4885
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG CYP17A1 4265/4885MEN1 2784/4885KMT2A 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.